Argenx Se (ARGX) — SEC Filings

Overview

Argenx Se (ARGX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Dec 15, 2025: Argenx SE filed a Form 6-K on December 15, 2025, reporting for the month of December 2025. The company, a biopharmaceutical firm specializing in biological products, is registered with the SEC under file number 001-38097. Its principal executive offices are located in Amsterdam, the Netherlands.

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 10 bullish, 40 neutral. The dominant filing sentiment for Argenx Se is neutral.

Filing Type Overview

Argenx Se (ARGX) has filed 42 6-K, 2 20-F, 5 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

• 6-K Filing — 6-K · Apr 20, 2026
• Argenx SE Files December 2025 6-K Report — 6-K · Dec 15, 2025 Risk: low
  Argenx SE filed a Form 6-K on December 15, 2025, reporting for the month of December 2025. The company, a biopharmaceutical firm specializing in biological prod
• 6-K Filing — 6-K · Nov 18, 2025
• Argenx SE Files 6-K Report — 6-K · Oct 30, 2025 Risk: low
  Argenx SE filed a Form 6-K on October 30, 2025, reporting for the period ending September 30, 2025. The filing is a report of a foreign private issuer and inclu
• Argenx SE Files 6-K Report — 6-K · Oct 29, 2025 Risk: low
  Argenx SE filed a Form 6-K on October 29, 2025, reporting as a foreign private issuer. The filing provides information for the month of October 2025 and indicat
• Argenx SE Files October 2025 6-K Report — 6-K · Oct 15, 2025 Risk: low
  Argenx SE filed a Form 6-K on October 15, 2025, reporting information for the month of October 2025. The filing is from their principal executive offices locate
• Argenx SE Files October 2025 6-K Report — 6-K · Oct 3, 2025 Risk: low
  Argenx SE filed a Form 6-K on October 3, 2025, reporting for the month of October 2025. The filing is from a foreign private issuer and is submitted under Rule
• Argenx SE Files August 2025 6-K Report — 6-K · Aug 25, 2025 Risk: low
  Argenx SE filed a Form 6-K on August 25, 2025, reporting for the month of August 2025. The company, a foreign private issuer, is based in Zwijnaarde, Belgium, a
• arGEN-X SE Files 6-K with H1 2025 Financials — 6-K · Jul 31, 2025 Risk: low
  On July 31, 2025, arGEN-X SE filed a 6-K report for the period ending June 30, 2025. The filing includes financial data for the first half of 2025 and the full
• argenx SE Files Form 6-K — 6-K · Jun 30, 2025 Risk: low
  On June 30, 2025, argenx SE issued a press release. The filing is a Form 6-K, which is a report of a foreign private issuer. The company's principal executive o
• argenX SE Files Form 6-K with SEC — 6-K · Jun 20, 2025 Risk: low
  On June 20, 2025, argenx SE announced the issuance of a press release. The filing is a Form 6-K, which is a report of a foreign private issuer submitted to the
• argenx SE Q1 2025 Results: Revenue Soars, Net Loss Narrows — 6-K · Jun 11, 2025 Risk: medium
  On June 10, 2025, argenx SE announced the publication of its first quarter 2025 financial results. The company reported total revenue of $178.1 million for Q1 2
• argenx SE Q1 2025 Results & Business Update — 6-K · May 28, 2025 Risk: medium
  On May 28, 2025, argenx SE announced the publication of its first quarter 2025 financial results and provided a business update. The company reported total reve
• argenx SE Files Form 6-K for Q1 2025 Reporting — 6-K · May 8, 2025 Risk: low
  On May 8, 2025, argenx SE filed a Form 6-K, reporting information for the period ending March 31, 2025. The filing includes details about the company's operatio
• Argenx SE Files Form 6-K with SEC — 6-K · Apr 28, 2025 Risk: low
  On April 28, 2025, argenx SE announced the issuance of a press release. The filing is a Form 6-K, which is a report of a foreign private issuer submitted to the
• argenx SE Announces Annual General Meeting — 6-K · Apr 14, 2025 Risk: low
  On April 11, 2025, argenx SE announced its upcoming annual general meeting. The company, a biopharmaceutical firm focused on autoimmune diseases, is based in Zw
• argenx Q1 2025 Results Show Strong Revenue Growth — 6-K · Apr 11, 2025 Risk: medium
  On April 10, 2025, argenx SE issued a press release announcing its first quarter 2025 financial results. The company reported total revenue of $1.2 billion for
• argenX SE Files April 2025 6-K Report — 6-K · Apr 8, 2025 Risk: low
  On April 8, 2025, argenx SE filed a Form 6-K with the SEC. This report is for the month of April 2025 and is filed by a foreign private issuer. The company's pr
• Argenx SE Files 2024 Annual Report — 20-F · Mar 20, 2025 Risk: medium
  Argenx SE filed its 20-F annual report for the fiscal year ending December 31, 2024. The report details the company's financial performance and business operati
• Argenx SE Files 6-K Report — 6-K · Mar 7, 2025 Risk: low
  On March 7, 2025, argenx SE filed a Form 6-K, reporting its status as a foreign private issuer. The filing provides information regarding the company's principa
• argenx SE Files February 2025 Form 6-K — 6-K · Feb 27, 2025 Risk: low
  On February 27, 2025, argenx SE filed a Form 6-K report. This filing is for the month of February 2025 and pertains to the period ending December 31, 2024. The
• argenx to Present at J.P. Morgan Healthcare Conference — 6-K · Jan 13, 2025 Risk: low
  On January 13, 2025, argenx SE announced its participation in the upcoming 43rd Annual J.P. Morgan Healthcare Conference. The company will present on January 15
• argenX SE Files Form 6-K for December 2024 — 6-K · Dec 27, 2024 Risk: low
  On December 27, 2024, argenx SE announced the issuance of a press release. This filing is a Form 6-K report of a foreign private issuer, indicating it is provid
• argenx SE Files November 2024 Report on Form 6-K — 6-K · Nov 20, 2024 Risk: low
  On November 20, 2024, argenx SE filed a Form 6-K, reporting its activities for the month of November 2024. The filing is a report of a foreign private issuer pu
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• argenx SE Q3 2024 Results Show Strong Revenue Growth — 6-K · Nov 12, 2024 Risk: medium
  On November 11, 2024, argenx SE announced the publication of its third quarter 2024 financial results. The company reported total revenue of $220.5 million for
• SC 13G/A Filing — SC 13G/A · Nov 12, 2024
• argenx SE Files October 2024 6-K Report — 6-K · Oct 31, 2024 Risk: low
  On October 31, 2024, argenx SE filed a Form 6-K, reporting on its activities for the month of October 2024. The filing is a report of a foreign private issuer a
• argenx SE Files 6-K Report — 6-K · Oct 15, 2024 Risk: low
  On October 15, 2024, argenx SE issued a press release to report on its business and financial updates. The company, headquartered in Amsterdam, the Netherlands,
• Argenx SE Files 6-K Report — 6-K · Sep 19, 2024 Risk: low
  On September 19, 2024, argenx SE filed a Form 6-K, reporting its status as a foreign private issuer. The filing provides information regarding its principal exe
• Argenx SE Files Routine 6-K Report — 6-K · Jul 25, 2024 Risk: low
  Argenx SE filed a Form 6-K on July 25, 2024, reporting its financial and operational status as of June 30, 2024. The filing is a routine report for foreign priv
• argenx SE Reports Q2 2024 Results and Business Update — 6-K · Jul 16, 2024 Risk: medium
  On July 16, 2024, argenx SE announced the publication of its second quarter 2024 financial results and provided a business update. The company highlighted progr
• argenx SE Closes $1 Billion Convertible Notes Offering — 6-K · Jun 25, 2024 Risk: medium
  On June 25, 2024, argenx SE announced the closing of its previously announced offering of 0% convertible senior notes due 2031, raising approximately $1.0 billi
• argenx SE raises $1.465 billion in stock and notes offering — 6-K · Jun 24, 2024 Risk: medium
  On June 21, 2024, argenx SE announced the closing of its previously announced offering of 1,500,000 ordinary shares at a price of $310.00 per share, resulting i
• argenx SE raises over $2.5B from share and note offerings — 6-K · Jun 17, 2024 Risk: medium
  On June 17, 2024, argenx SE announced the closing of its previously announced offering of 1,725,000 ordinary shares at a price of $315.00 per share, resulting i
• argenx SE Q1 2024 Results Show Strong Revenue Growth — 6-K · May 9, 2024 Risk: medium
  On May 9, 2024, argenx SE announced its first quarter 2024 financial results. The company reported total revenue of $332 million, a significant increase driven
• argenX SE Announces AGM Voting Results — 6-K · May 8, 2024 Risk: low
  On May 7, 2024, argenx SE announced the voting results from its Annual General Meeting of Shareholders held on May 7, 2024. Key resolutions included the reappoi
• argenx SE Q1 2024 Update and Financial Results — 6-K · Apr 16, 2024 Risk: medium
  On April 16, 2024, argenx SE announced the publication of its first quarter 2024 financial results and provided a business update. The company highlighted its p
• argenx SE Announces Annual General Meeting Details — 6-K · Mar 27, 2024 Risk: low
  On March 26, 2024, argenx SE announced a convocation notice for its upcoming Annual General Meeting of Shareholders. The meeting is scheduled to take place on A
• argenx SE Reports Strong 2023 Financials and Pipeline Progress — 6-K · Mar 26, 2024 Risk: medium
  On March 26, 2024, argenx SE announced the publication of its fourth quarter and full year 2023 results. The company reported total revenue of €1.2 billion for
• arGENX SE Files March 2024 Report (6-K) — 6-K · Mar 21, 2024 Risk: low
  On March 21, 2024, arGENX SE filed a Form 6-K, reporting information for the month of March 2024. The filing indicates arGENX SE is a foreign private issuer and
• ARGENX SE Files 20-F Annual Report for Fiscal Year Ended December 31, 2023 — 20-F · Mar 21, 2024 Risk: medium
  ARGENX SE (ARGX) filed a Foreign Annual Report (20-F) with the SEC on March 21, 2024. ARGENX SE filed its 20-F annual report for the fiscal year ending December
• argenx SE Reports Q4 and FY 2023 Results — 6-K · Mar 8, 2024 Risk: medium
  On March 7, 2024, argenx SE announced the publication of its fourth quarter and full year 2023 results. The company reported strong financial performance and pr
• ARGENX SE Files 6-K for Press Release and Investor Presentation — 6-K · Feb 29, 2024 Risk: low
  ARGENX SE, a foreign private issuer, filed a Form 6-K on February 29, 2024, to report the issuance of a press release and an investor presentation. The company,
• ARGENX SE Files 6-K for February 2024 Press Release — 6-K · Feb 20, 2024 Risk: low
  ARGENX SE, a foreign private issuer, filed a Form 6-K on February 20, 2024, to report the issuance of a press release on the same date. The company, with Commis
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• Artisan Partners Discloses Passive Stake in Argenx SE — SC 13G · Feb 12, 2024 Risk: low
  Artisan Partners Limited Partnership, a Milwaukee-based investment firm, filed an SC 13G on February 12, 2024, disclosing its ownership of American Depositary S
• FMR LLC & Abigail Johnson Hold 7.064% Stake in ARGENX SE — SC 13G/A · Feb 9, 2024 Risk: low
  FMR LLC, a major investment firm, and its CEO, Abigail P. Johnson, have updated their ownership in ARGENX SE, a biological products company. As of February 9, 2
• BlackRock Updates ARGENX SE Stake as of Dec 31, 2023 — SC 13G/A · Feb 1, 2024
  BlackRock Inc. filed an amended SC 13G/A on February 1, 2024, indicating its ownership in ARGENX SE's Common Stock as of December 31, 2023. This filing, an amen
• ARGENX SE ANNOUNCES VYVDURA APPROVAL VIA 6-K FILING — 6-K · Jan 18, 2024
  On January 18, 2024, argenx SE announced the approval of VYVDURA, a significant development for the company. This 6-K filing indicates that argenx SE issued a p

Frequently Asked Questions